Author

M. Kamgar

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection

Metastatic pancreatic ductal adenocarcinoma (PDAC) has historically been managed with systemic therapy, and local therapies have, in general, been avoided in the absence of symptoms directly related to a specific metastasis. Even if a specific site of disease, such as a local recurrence, had the potential to cause symp...

Kshitij S. Gaur, W. Hall, M. Kamgar et al. · Cancers · 0 citations

Open access Aug 2026

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

Clinical-grade RAS inhibitors raise an unresolved question as to whether KRAS alleles impose constraints on adaptive resistance that can be exploited therapeutically. Using daraxonrasib (RMC-6236), a multi-selective RAS(ON) inhibitor, we compared resistance mechanisms between KRASG12D and KRASG12R, mutants with fundame...

Daniel Dorbin, Julia R. Herrera, R. Davidson et al. · Cancer Research · 1 citation · ⚡1

Sep 2026

Abstract B060: From Resistance to Rescue: Allele-Informed Salvage Therapy Following Daraxonrasib Resitance in Pancreatic Cancer

Clinical-grade RAS(ON) inhibitors have transformed treatment of KRAS-mutant pancreatic ductal adenocarcinoma (PDAC), but acquired resistance is universal and post-progression treatment selection remains empiric. Whether specific KRAS alleles impose distinct constraints on the adaptive resistance network, and whet...

T. McFall, Daniel Dorbin, Julia R. Herrera et al. · Cancer Research · 0 citations